Compare Moderna, Inc. (MRNA) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs S&P Global Inc — how do they compare? Moderna, Inc. trades at $197.19 (market cap $78.65B), while S&P Global Inc trades at $403.13 (market cap $118.72B). The key difference: S&P Global Inc is the larger of the two by market cap, and S&P Global Inc pays a 0.96% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and S&P Global Inc for 123 Days on average.
| MRNA | SPGI | |
|---|---|---|
Market Cap | $78.65B | $118.72B |
Volume | 37,373,437 | 1,647,917 |
Sector | Health | Financials |
52-Week High | $203.46 | $517.92 |
52-Week Low | $22.36 | $370.42 |
Typical Hold Time | 59 Days | 123 Days |
Enterprise Value | $74.80B | $130.21B |
Dividend Yield | — | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.
Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.
S&P Global (SPGI) trades at $395.18, down 0.24% on the day, with strong analyst support showing 85.7% buy ratings and a $509.50 consensus price target. The stock shows bearish technical signals but maintains robust fundamentals with 30.5% net margins and consistent revenue growth from $15.3B in 2025 to projected $16.1B in 2026. Recent developments include expansion into digital asset risk assessment and AI-driven growth initiatives.
The outlook remains positive given the company's dominant market position and financial strength, though technical weakness and high valuation multiples present near-term risks. Long-term growth drivers include AI integration and strategic acquisitions, while risks include market sensitivity to economic cycles and competitive pressures in financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
